Novo Nordisk raises full-year sales and profit outlook on Wegovy pill demand
FROM THE WIRE · FINANCE.YAHOO.COM
Novo Nordisk reported third quarter 2026 sales of DKK 79,195 million and net income of DKK 16,740 million, raised its full year sales and profit outlook, and cited strong demand for GLP 1 obesity and diabetes treatments, especially the Wegovy pill. The earnings update showed…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishRaised full-year guidance from a major pharma company is relevant for the sector and broader market.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Novo Nordisk reported Q3 2026 sales of DKK 79,195 million.
- 02Net income was DKK 16,740 million, and full-year outlook was raised.
- 03Meaningful U.S. list price cuts for Wegovy and Ozempic are planned from January 2027.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets